Published in Bioorg Med Chem Lett on November 04, 2002
Dendritic cell PAR1-S1P3 signalling couples coagulation and inflammation. Nature (2008) 3.14
Role of tissue factor and protease-activated receptors in a mouse model of endotoxemia. Blood (2003) 2.20
Induction of intestinal inflammation in mouse by activation of proteinase-activated receptor-2. Am J Pathol (2002) 2.16
Role for protease activity in visceral pain in irritable bowel syndrome. J Clin Invest (2007) 2.09
Protease-activated receptor-1 contributes to cardiac remodeling and hypertrophy. Circulation (2007) 1.97
Mer receptor tyrosine kinase signaling participates in platelet function. Arterioscler Thromb Vasc Biol (2004) 1.67
Reduction in glucagon receptor expression by an antisense oligonucleotide ameliorates diabetic syndrome in db/db mice. Diabetes (2004) 1.65
Proteinase-activated receptors, targets for kallikrein signaling. J Biol Chem (2006) 1.63
Blocking the protease-activated receptor 1-4 heterodimer in platelet-mediated thrombosis. Circulation (2006) 1.60
Protease-activated receptor (PAR) 2, but not PAR1, signaling promotes the development of mammary adenocarcinoma in polyoma middle T mice. Cancer Res (2008) 1.50
A major role for proteolytic activity and proteinase-activated receptor-2 in the pathogenesis of infectious colitis. Proc Natl Acad Sci U S A (2005) 1.45
Human cardiomyocytes express high level of Na+/glucose cotransporter 1 (SGLT1). J Cell Biochem (2003) 1.36
Role of protease activated receptor 1 and 2 signaling in hypoxia-induced angiogenesis. Arterioscler Thromb Vasc Biol (2007) 1.33
Protection against acute pancreatitis by activation of protease-activated receptor-2. Am J Physiol Gastrointest Liver Physiol (2004) 1.29
Proteinase-activated receptor 2 modulates neuroinflammation in experimental autoimmune encephalomyelitis and multiple sclerosis. J Exp Med (2006) 1.25
Proinflammatory role of proteinase-activated receptor-2 in humans and mice during cutaneous inflammation in vivo. FASEB J (2003) 1.22
Blockade of the thrombin receptor protease-activated receptor-1 with a small-molecule antagonist prevents thrombus formation and vascular occlusion in nonhuman primates. J Pharmacol Exp Ther (2003) 1.20
Protective role for protease-activated receptor-2 against influenza virus pathogenesis via an IFN-gamma-dependent pathway. J Immunol (2009) 1.19
Thrombogenic collagen-mimetic peptides: Self-assembly of triple helix-based fibrils driven by hydrophobic interactions. Proc Natl Acad Sci U S A (2008) 1.18
Recent advances in peroxisome proliferator-activated receptor science. Curr Med Chem (2003) 1.15
Retracted A role for proteinase-activated receptor-1 in inflammatory bowel diseases. J Clin Invest (2004) 1.15
Participation of protease-activated receptor-1 in thrombin-induced microglial activation. J Neurochem (2002) 1.12
In-depth study of tripeptide-based alpha-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1' subsite and its implications to structure-based drug design. J Med Chem (2005) 1.12
Plasmin induces Cyr61 gene expression in fibroblasts via protease-activated receptor-1 and p44/42 mitogen-activated protein kinase-dependent signaling pathway. Arterioscler Thromb Vasc Biol (2002) 1.10
Characterization of thrombin-induced leukocyte rolling and adherence: a potential proinflammatory role for proteinase-activated receptor-4. J Immunol (2002) 1.10
Neutrophil cathepsin G promotes detachment-induced cardiomyocyte apoptosis via a protease-activated receptor-independent mechanism. J Biol Chem (2003) 1.10
Collagen-related peptides: self-assembly of short, single strands into a functional biomaterial of micrometer scale. J Am Chem Soc (2007) 1.09
Trimethylsilyl-directed 1,3-dipolar cycloaddition reactions in the solid-phase synthesis of 1,2,3-triazoles. Org Lett (2005) 1.08
Protease-activated receptor-2 activation: a major role in the pathogenesis of Porphyromonas gingivalis infection. Am J Pathol (2006) 1.07
Molecular pharmacodynamics, clinical therapeutics, and pharmacokinetics of topiramate. CNS Neurosci Ther (2008) 1.06
Extracellular mediators in atherosclerosis and thrombosis: lessons from thrombin receptor knockout mice. Arterioscler Thromb Vasc Biol (2003) 1.05
Proteinase-activated receptor-2 induction by neuroinflammation prevents neuronal death during HIV infection. J Immunol (2005) 1.04
Expression of protease-activated receptor-1, -2, -3, and -4 in control and experimentally inflamed mouse bladder. Am J Pathol (2003) 1.04
Synthesis and biological evaluation of 3-aryl-3-(4-phenoxy)-propionic acid as a novel series of G protein-coupled receptor 40 agonists. J Med Chem (2007) 1.03
Multiple mechanisms of vascular smooth muscle relaxation by the activation of proteinase-activated receptor 2 in mouse mesenteric arterioles. Br J Pharmacol (2002) 1.03
Synthesis of macrocycles via cobalt-mediated [2 + 2 + 2] cycloadditions. J Am Chem Soc (2005) 1.02
Urotensin II is a nitric oxide-dependent vasodilator and natriuretic peptide in the rat kidney. Am J Physiol Renal Physiol (2003) 1.00
Mechanisms of protease-activated receptor-4 actions in cardiomyocytes. Role of Src tyrosine kinase. J Biol Chem (2003) 0.99
Novel piperidinyloxy oxazolidinone antibacterial agents. Diversification of the N-Substituent. Bioorg Med Chem (2002) 0.98
Molecules that mimic apolipoprotein A-I: potential agents for treating atherosclerosis. J Med Chem (2013) 0.98
A novel, potent dual inhibitor of the leukocyte proteases cathepsin G and chymase: molecular mechanisms and anti-inflammatory activity in vivo. J Biol Chem (2005) 0.96
Cycloaddition reactions of thiazolium azomethine ylides: application to pyrrolo[2,1-b]thiazoles. Org Lett (2007) 0.96
Potent, small-molecule inhibitors of human mast cell tryptase. Antiasthmatic action of a dipeptide-based transition-state analogue containing a benzothiazole ketone. J Med Chem (2003) 0.96
Design, synthesis, and biological evaluation of novel 7-azaindolyl-heteroaryl-maleimides as potent and selective glycogen synthase kinase-3beta (GSK-3beta) inhibitors. Bioorg Med Chem (2004) 0.95
Mimicry of high-density lipoprotein: functional peptide-lipid nanoparticles based on multivalent peptide constructs. J Am Chem Soc (2013) 0.94
Proteinase-activated receptor-2 exerts protective and pathogenic cell type-specific effects in Alzheimer's disease. J Immunol (2007) 0.93
Regulatory network of inflammation downstream of proteinase-activated receptors. BMC Physiol (2007) 0.93
Allometric scaling of pharmacokinetic parameters in drug discovery: can human CL, Vss and t1/2 be predicted from in-vivo rat data? Eur J Drug Metab Pharmacokinet (2004) 0.92
Discovery of potent, selective, orally active, nonpeptide inhibitors of human mast cell chymase. J Med Chem (2007) 0.92
Dual inhibition of cathepsin G and chymase is effective in animal models of pulmonary inflammation. Am J Respir Crit Care Med (2009) 0.92
Proteinase-activated receptor-2 (PAR2): vascular effects of a PAR2-derived activating peptide via a receptor different than PAR2. J Pharmacol Exp Ther (2002) 0.92
Mandatory role of proteinase-activated receptor 1 in experimental bladder inflammation. BMC Physiol (2007) 0.91
Benzoxazinones as PPARgamma agonists. 2. SAR of the amide substituent and in vivo results in a type 2 diabetes model. J Med Chem (2004) 0.91
Studies with an orally bioavailable alpha V integrin antagonist in animal models of ocular vasculopathy: retinal neovascularization in mice and retinal vascular permeability in diabetic rats. J Pharmacol Exp Ther (2007) 0.91
The use of stable isotope-labeled glycerol and oleic acid to differentiate the hepatic functions of DGAT1 and -2. J Lipid Res (2012) 0.90
Nonpeptide urotensin-II receptor antagonists: a new ligand class based on piperazino-phthalimide and piperazino-isoindolinone subunits. J Med Chem (2009) 0.90
Inhibition of carbonic anhydrase-II by sulfamate and sulfamide groups: an investigation involving direct thermodynamic binding measurements. J Med Chem (2006) 0.89
Therapeutic potential of protease-activated receptor-1 antagonists. Expert Opin Investig Drugs (2003) 0.89
Proteinase-activated receptor-1 is an anti-inflammatory signal for colitis mediated by a type 2 immune response. Inflamm Bowel Dis (2005) 0.89
Novel bis(indolyl)maleimide pyridinophanes that are potent, selective inhibitors of glycogen synthase kinase-3. Bioorg Med Chem Lett (2007) 0.89
RWJ-58259: a selective antagonist of protease activated receptor-1. Cardiovasc Drug Rev (2003) 0.87
The use of formic acid to embellish amyloid plaque detection in Alzheimer's disease tissues misguides key observations. Neurosci Lett (2003) 0.86
Lipofuscin and Abeta42 exhibit distinct distribution patterns in normal and Alzheimer's disease brains. Neurosci Lett (2002) 0.86
Design and synthesis of potent inhibitors of cholesteryl ester transfer protein (CETP) exploiting a 1,2,3,4-tetrahydroquinoline platform. Bioorg Med Chem Lett (2009) 0.86
Mechanisms underlying the nociceptive and inflammatory responses induced by trypsin in the mouse paw. Eur J Pharmacol (2007) 0.86
Intrathecal administration of proteinase-activated receptor-2 agonists produces hyperalgesia by exciting the cell bodies of primary sensory neurons. J Pharmacol Exp Ther (2007) 0.86
Synthesis and antibacterial activity of pyrroloaryl-substituted oxazolidinones. Bioorg Med Chem Lett (2003) 0.86
Glycosylated dihydrochalcones as potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitors. Bioorg Med Chem Lett (2004) 0.85
Structure-function analysis of urotensin II and its use in the construction of a ligand-receptor working model. Angew Chem Int Ed Engl (2002) 0.85
Arterial antithrombotic activity of rivaroxaban, an orally active factor Xa inhibitor, in a rat electrolytic carotid artery injury model of thrombosis. Blood Coagul Fibrinolysis (2011) 0.85
Cobalt-mediated cyclotrimerisation of bis-alkynes and cyanamides. Chem Commun (Camb) (2004) 0.85
Discovery of potent peptide-mimetic antagonists for the human thrombin receptor, protease-activated receptor-1 (PAR-1). Curr Med Chem Cardiovasc Hematol Agents (2003) 0.85
Human epidermoid A431 cells express functional nicotinic acid receptor HM74a. Mol Cell Biochem (2006) 0.85
Synthesis and discovery of macrocyclic polyoxygenated bis-7-azaindolylmaleimides as a novel series of potent and highly selective glycogen synthase kinase-3beta inhibitors. J Med Chem (2003) 0.85
7-fluoroindazoles as potent and selective inhibitors of factor Xa. J Med Chem (2007) 0.85
Potency variation of small-molecule chymase inhibitors across species. Biochem Pharmacol (2010) 0.84
Serine protease inhibition reduces post-ischemic granulocyte recruitment in mouse intestine. Am J Pathol (2011) 0.84
Discovery of fused bicyclic agonists of the orphan G-protein coupled receptor GPR119 with in vivo activity in rodent models of glucose control. Bioorg Med Chem Lett (2011) 0.84
Nanoparticles that display short collagen-related peptides. Potent stimulation of human platelet aggregation by triple helical motifs. Bioconjug Chem (2007) 0.84
Activation of proteinase-activated receptor-1 inhibits neurally evoked chloride secretion in the mouse colon in vitro. Am J Physiol Gastrointest Liver Physiol (2004) 0.84
Thrombin receptor: An endogenous inhibitor of inflammatory pain, activating opioid pathways. Pain (2009) 0.84
Pharmacokinetic and metabolic investigation of topiramate disposition in healthy subjects in the absence and in the presence of enzyme induction by carbamazepine. Epilepsia (2005) 0.84
Analysis of topiramate and its metabolites in plasma and urine of healthy subjects and patients with epilepsy by use of a novel liquid chromatography-mass spectrometry assay. Ther Drug Monit (2003) 0.84
Enhancement of arachidonic acid signaling pathway by nicotinic acid receptor HM74A. Biochem Biophys Res Commun (2006) 0.83